Xenon Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 09, 2023 16:01 ET
|
Xenon Pharmaceuticals Inc.
XEN1101 Phase 3 epilepsy program continues to make significant progress across all ongoing clinical trials including the recent initiation of X-TOLE3 in addition to the ongoing X-TOLE2 and X-ACKT...
Xenon Pharmaceuticals to Present at the BofA Securities Health Care Conference 2023
May 03, 2023 16:01 ET
|
Xenon Pharmaceuticals Inc.
VANCOUVER, British Columbia, May 03, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present...
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Corporate Update
May 02, 2023 16:01 ET
|
Xenon Pharmaceuticals Inc.
VANCOUVER, British Columbia, May 02, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its first...
Xenon Pharmaceuticals Showcases Its XEN1101 Epilepsy Program at the 2023 American Academy of Neurology (AAN) Annual Meeting
April 24, 2023 08:00 ET
|
Xenon Pharmaceuticals Inc.
Oral presentation by Dr. Jacqueline French to outline sustained monthly reduction in focal onset seizures during open-label extension of X-TOLE study Poster to present the trial design for Phase 3...
Xenon Pharmaceuticals to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
April 21, 2023 16:01 ET
|
Xenon Pharmaceuticals Inc.
BURNABY, British Columbia, April 21, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that it will host a company...
Xenon Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference
April 18, 2023 08:15 ET
|
Xenon Pharmaceuticals Inc.
BURNABY, British Columbia, April 18, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present...
Xenon Pharmaceuticals to Present at the Stifel 2023 CNS Days
March 22, 2023 16:01 ET
|
Xenon Pharmaceuticals Inc.
BURNABY, British Columbia, March 22, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present...
Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
March 01, 2023 16:01 ET
|
Xenon Pharmaceuticals Inc.
XEN1101 Phase 3 epilepsy program continues to advance in focal onset seizures and primary generalized tonic clonic seizures Topline data from XEN1101 Phase 2 X-NOVA clinical trial in major...
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update
February 22, 2023 16:01 ET
|
Xenon Pharmaceuticals Inc.
BURNABY, British Columbia, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its fourth...
Xenon Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference
February 08, 2023 16:01 ET
|
Xenon Pharmaceuticals Inc.
BURNABY, British Columbia, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at...